News
BDRX
2.380
-0.83%
-0.020
Biodexa Reports Serenta Trial Two-Thirds Enrolled, MTX240 Preparations Advance
TipRanks · 3d ago
Biodexa Pharma Announces Further Progress In Both Its Lead Programs; eRapa For Familial Adenomatous Polyposis And MTX240 Molecular Glue For Gastrointestinal Stromal Tumors
Benzinga · 3d ago
Weekly Report: what happened at BDRX last week (1102-1106)?
Weekly Report · 3d ago
Short Interest Alert: Most and least shorted sub-$2B healthcare stock at the end of October
Seeking Alpha · 11/03 15:15
Weekly Report: what happened at BDRX last week (1026-1030)?
Weekly Report · 11/02 09:54
Biodexa Pharmaceuticals Plc - Depositary Receipt Price Target Increased by 700.00% to $73.44
NASDAQ · 11/02 04:12
Stock Splits on Deck This Week (October 26 to October 30) – Stay Invested
TipRanks · 10/26 13:06
Weekly Report: what happened at BDRX last week (1019-1023)?
Weekly Report · 10/26 09:54
Biodexa Pharmaceuticals PLC-ADR trading halted, news pending
TipRanks · 10/23 23:50
Weekly Report: what happened at BDRX last week (1012-1016)?
Weekly Report · 10/19 09:54
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 10/14 21:06
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 10/14 17:06
Biodexa Reaches 100-Patient Milestone in Phase 3 Serenta Trial for FAP
TipRanks · 10/14 13:02
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 10/14 12:06
Why Enovix Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/14 08:51
Biodexa Pharmaceuticals enrolls 100 patients in eRapa trial
TipRanks · 10/13 13:00
Biodexa Pharmaceuticals Enrolls 100 Patients In Its Registrational Phase 3 Serenta Trial Of eRapa In Familial Adenomatous Polyposis; Trial Is Recruiting At 29 Clinical Sites In U.S., Canada And Europe And Is Expected To Be Initiated Shortly
Benzinga · 10/13 12:34
Weekly Report: what happened at BDRX last week (1005-1009)?
Weekly Report · 10/12 09:58
Biodexa Pharmaceuticals Announces Reverse ADS Ratio Change Effective Late October 2026
TipRanks · 10/08 20:28
CORRECTION: Biodexa Pharmaceuticals Announces 1-For-8 Reverse ADS Split, Effective October 26
Benzinga · 10/08 20:16
More
Webull provides a variety of real-time BDRX stock news. You can receive the latest news about Biodexa Pharmaceuticals plc through multiple platforms. This information may help you make smarter investment decisions.
About BDRX
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.